~~<i id='5AD0C9E001'><strike id='5AD0C9E001'><tt id='5AD0C9E001'><pre id='5AD0C9E001'></pre></tt></strike></i>~~

Home» focus» focus

focus

author：hotspot 2025-09-28 17:52:42 Page View：9

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Grail spinoff by Illumina should end disastrous merger attempt
Next article： Drug repurposing or repositioning? The language matters

explore

United colonoscopy coverage change 'may cost lives,' doctors say

AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

CDC wastewater surveillance dashboard to track bird flu hotspots

GodofredoA.Vásquez/APReluctanceamongdairyfarmerstoreportH5N1birdfluoutbreakswithintheirherdsorallowt

Peter Hotez and the public health issue of online harassment

AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

Making AI in medicine accessible to smaller, and rural hospitals

NorthCountryHealthCareInKingman,Ariz.,awindsweptcityof35,000attheeasternedgeoftheMojavedesert,datasc

WSS

focus

focus

leisure time

explore

Making AI in medicine accessible to smaller, and rural hospitals